Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs. October 5, 2016
Suppressing Schizophrenia Symptoms Without Side Effects: Mouse Study September 20, 2016
Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine. (2016) April 28, 2016
Microglia and stress April 9, 2016
Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model. (2016) February 10, 2016
Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial (2015) December 24, 2015
Ketogenic Diets December 18, 2015
Madness and the Family (Part One): The History and Research of Family Dynamics and Psychosis December 15, 2015
Recovering From Psychiatry- The Power of Psychiatric Diagnosis December 14, 2015
Focus on the symptoms instead of on the illness and solve the ‘schizophrenia’ problem December 8, 2015
Mindfulness and dissociation December 3, 2015
Cyproheptadine for sleep? December 2, 2015
Rethinking psychopharmacotherapy: The role of treatment context and brain plasticity in antidepressant and antipsychotic interventions (2015) December 2, 2015
Exercise Improves Clinical Symptoms, Quality of Life, Global Functioning, and Depression in Schizophrenia: A Systematic Review and Meta-analysis (2015) December 1, 2015
Exploring the overlap between ASD, Schizoid Personality and Schizophrenia November 30, 2015
Adjunctive use of lisdexamfetamine November 27, 2015
The role of inflammation in schizophrenia. (2015) November 26, 2015
Anxiety in Patients with Schizophrenia: Epidemiology and Management (2015) November 26, 2015
A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) November 26, 2015
Struggling with schizophrenia and sexuality October 23, 2015
New pharmacotherapy targeting the improvement of GABA neuronal function for the cognitive dysfunction of schizophrenia. (2015) October 19, 2015
Positive Emotions Program for Schizophrenia (PEPS): a pilot intervention to reduce anhedonia and apathy. (2015) October 2, 2015
Supplementation of antipsychotic treatment with sarcosine-G1yT1 inhibitor-causes changes of glutamatergic 1NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia. (2015) August 27, 2015
Auditory verbal hallucinations in schizophrenia and post-traumatic stress disorder: common phenomenology, common cause, common interventions? (2015) August 21, 2015
Antipsychotic Maintenance Treatment: Time to Rethink? (2015) August 17, 2015
SRC inhibitors as potential antipsychotics: human testing with psilocybin August 9, 2015
Clozapine discontinuation – some experiences and a new animal model of schizophrenia August 6, 2015
A focus on nAChRs August 3, 2015
Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology (2015) August 2, 2015
Managing Stigma Effectively: What Social Psychology and Social Neuroscience Can Teach Us (2015) August 2, 2015
Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca’s area volume (2015) July 31, 2015
Recognition of cognitive impairment in schizophrenia July 30, 2015
Add-on Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial (2015) July 29, 2015
My trials with supplements for schizophrenia July 29, 2015
Improving cognition via vegetable derived NO? Polyphenols? July 28, 2015
GlyT1 inhibitors July 27, 2015
Social defeat models of schizophrenia July 27, 2015
Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review. (2015) July 25, 2015
30mg of aripiprazole – some experiences. Tackling cravings? The DAergic effects of stress? July 24, 2015
Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder (2015) July 23, 2015
Riluzole and Memantine: Attenuating early-life stress-induced disturbances to the reward system by modulating glutamatergic transmission during adolescence ? July 20, 2015
Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia (2015) July 15, 2015
A single dose of oxytocin nasal spray improves higher-order social cognition in schizophrenia. (2015) July 13, 2015
A focus on estrogens July 9, 2015
More on NMDARs July 7, 2015
Improving the functional selectivity of D2 receptor ligands July 7, 2015
A focus on norepinephrine July 7, 2015
Inflammation in schizophrenia: A question of balance (2015) July 3, 2015
Synchronizing theta oscillations with direct-current stimulation strengthens adaptive control in the human brain. (2015) July 2, 2015
Inflammation and microglia July 2, 2015
A focus on the 5-HT6 receptor July 1, 2015
A focus on the 5-HT7 receptor July 1, 2015
Clinical Management of Negative Symptoms of Schizophrenia: An update (2015) June 29, 2015
Positive disintegration – a path to the resolution of ‘psychosis’? June 28, 2015
Auditory hallucinations: A review of the ERC “VOICE” project (2015) June 27, 2015
Understanding Madness: Science, Philosophy, and the Experience of Delusions (2015) June 27, 2015
The unconscious meets neuroscience… a focus on mAChRs June 26, 2015
Dietary Intake of Sulforaphane-Rich Broccoli Sprout Extracts during Juvenile and Adolescence Can Prevent Phencyclidine-Induced Cognitive Deficits at Adulthood. (2015) June 26, 2015
Trauma-related dissociation and altered states of consciousness: a call for clinical, treatment, and neuroscience research (2015) June 25, 2015
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms (2015) June 23, 2015
Auditory Hallucinations May Vary Across Cultures June 22, 2015
Gamma Rhythms, Prefrontal Interneuron Dysfunction and Cognitive Inflexibility June 22, 2015
‘Hearing voices’, ‘pseudohallucinations’ and ‘lucid dreams’ June 21, 2015
A Neurophysiological and Neuropsychological Consideration of Mindful Movement: Clinical and Research Implications. (2015) June 20, 2015
Dietary glycemic index as a modulator of behavioral and biochemical abnormalities? June 19, 2015
A focus on memantine June 19, 2015
Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. (2015) June 19, 2015
Journaling as Therapy (2015) June 17, 2015
The Differentiation of Psychosis and Spiritual Emergency (2008) June 13, 2015
Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia. (2015) June 12, 2015
Restoring a healthy gut? May 25, 2015
Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress (2015) May 24, 2015
Pharmacological disruption of maladaptive memory (from: Cognitive Enhancement – 2015) May 21, 2015
Sex differences, hormones, and fMRI stress response circuitry deficits in psychoses (2015) May 19, 2015
Levothyroxine Augmentation in Clozapine Resistant Schizophrenia: A Case Report and Review (2015) May 17, 2015
Diet, metabolic syndrome and schizophrenia/ASD – a convergence on PPAR-α? May 11, 2015
Augmentation with pregabalin in schizophrenia May 8, 2015
Targeting GABAB receptors May 8, 2015
The Magic of Movement; the Potential of Exercise to Improve Cognition (2015) May 6, 2015
New Targets for Prevention of Schizophrenia: Is it Time for Interventions in the Premorbid Phase? (2015) May 5, 2015
Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review (2015) May 1, 2015
Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms (2015) May 1, 2015
D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial (2015) May 1, 2015
Effect of l-theanine on glutamatergic function in patients with schizophrenia (2015) April 29, 2015
Glutamate as a mediating transmitter for auditory hallucinations in schizophrenia – an opportunity to target NO? April 25, 2015
Cognitive enhancing agents in schizophrenia and bipolar disorder (2015) April 23, 2015
Cannabidiol (CBD) April 22, 2015
Tailoring ratios of clozapine to N-desmethylclozapine (norclozapine) April 15, 2015
Drug repurposing and emerging adjunctive treatments for schizophrenia (2015) April 14, 2015
Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia – preliminary study. (2015) April 9, 2015
D-serine and DAAO inhibitors as therapeutics April 9, 2015
Quitting smoking – some thoughts April 2, 2015
Transcranial direct current stimulation as a treatment for auditory hallucinations. (2015) March 26, 2015
The effect of listening to music on human transcriptome. (2015) March 16, 2015
Love and positive emotions as a therapeutic target March 16, 2015
The Trace Amine-Associated Receptor 1 (TAAR1) March 13, 2015
Role of Inflammation in Psychiatric Disease (2015) March 12, 2015
Pharmacological Treatment of Cognitive Symptoms March 11, 2015
The Seasons of Wellbeing as an Evolutionary Map for Transpersonal Medicine (2015) March 9, 2015
More simply human: on the Universality of Madness (2015) March 8, 2015
Clinical perspectives on the relationship between psychosis and dissociation: utility of structural dissociation and implications for practice (2015) March 8, 2015
Third-wave strategies for emotion regulation in early psychosis: a pilot study (2015) March 1, 2015
Pro-social Priming March 1, 2015
Do expensive drugs work better than cheap ones? February 26, 2015
Novel Treatments of Psychosis (2015) February 21, 2015
Deconstructing mental illness through ultradian rhythms February 21, 2015
Biomarker Symptom Profiles for Schizophrenia and Schizoaffective Psychosis (2015) February 20, 2015
Are psychological therapies effective in treating schizophrenia and psychosis? (2015) February 20, 2015
Recovery, not progressive deterioration, should be the expectation in schizophrenia (2015) February 14, 2015
Epigenetics – a review of the literature February 9, 2015
‘Personal Paradigm Shifts’ and Recovery February 8, 2015
Subtyping Auditory Verbal Hallucinations and Its Implications for Research and Practice February 8, 2015
Targeting endocannabinoid pathways February 7, 2015
The Sigma-1 Receptor February 1, 2015
Attenuating antipsychotic-induced weight gain and metabolic side effects February 1, 2015
Stage specific and prophylactic treatments? January 31, 2015
A role for the microbiome in schizophrenia? January 31, 2015
Are some Auditory Verbal Hallucinations trauma/fear memories that are amendable via therapy & pharmacologically enhanced reconsolidation/extinction? January 29, 2015
Lipo-oxytocin-1, a Novel Oxytocin Analog Conjugated with Two Palmitoyl Groups, Has Long-Lasting Effects on Anxiety-Related Behavior and Social Avoidance in CD157 Knockout Mice. (2015) January 29, 2015
Neurosteroids as therapeutics January 29, 2015
Small Molecule Therapeutics for Schizophrenia (2015) January 29, 2015
Tackling negative/cognitive symptoms and other novel treatments January 29, 2015
Glycine, NMDA and AMPA augmentation – a review January 29, 2015
Augmenting in clozapine non/partial responders January 29, 2015
Sodium nitroprusside – a rapid acting antipsychotic January 29, 2015
Dietary and nutritional therapies for schizophrenia January 29, 2015
Natural products for schizophrenia January 28, 2015

Share this:

Like this:

Related

Leave a Reply Cancel reply